更新于：2024-11-15
Sertraline Hydrochloride
盐酸舍曲林
更新于：2024-11-15
概要
基本信息
简介舍曲林（Sertraline）是一种常用的抗抑郁药物，属于选择性5-羟色胺再摄取抑制剂（SSRI）类药物。它用于治疗成人和儿童的抑郁症、焦虑症和强迫症。舍曲林通过增加大脑中调节情绪的神经递质5-羟色胺的水平发挥作用。它通常每天一次，可随餐或空腹服用，可能需要数周才会开始发挥作用。像所有药物一样，舍曲林也有潜在的副作用，包括恶心、失眠和性功能障碍。与医疗保健提供者合作，确定舍曲林是否是治疗特定情况的好选择是非常重要的。 |
药物类型 小分子化药 |
别名 Aremis、Besitran、Gladem + [19] |
靶点 |
作用机制 5-羟色胺重摄取抑制剂 |
治疗领域 |
非在研适应症- |
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C17H18Cl3N |
InChIKeyBLFQGGGGFNSJKA-XHXSRVRCSA-N |
CAS号79559-97-0 |
关联
283
项与 盐酸舍曲林 相关的临床试验ACE-D: Accelerating Cognition-guided Signatures to Enhance Translation in Depression: Clinical Trial
EASE: Evaluating Antidepressants for emotionaliSm after strokE: a multi-centre, randomised, double-blind, placebo-controlled trial to establish the effect(s) of administration of sertraline (50 mg once daily for 6 months) in people with a recent stroke and post-stroke emotionalism
A Randomised, Controlled Trial to Investigate the Effect of an Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
100 项与 盐酸舍曲林 相关的临床结果
登录后查看更多信息
100 项与 盐酸舍曲林 相关的转化医学
登录后查看更多信息
100 项与 盐酸舍曲林 相关的专利（医药）
登录后查看更多信息
5,420
项与 盐酸舍曲林 相关的文献（医药）2025-01-01JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
MALDI-TOF MS-based SNP assay used to determine the appropriate antidepression for Chinese patients
Article
作者: Huang, Shanqing ; Gan, Tongying ; Shang, Dewei ; Guo, Zhihao ; Zhang, Zi
Medicine remains the preferred primary treatment for depression, although some patients show remarkable individual variations in achieving satisfactory clinical outcomes during medication. Genetic polymorphisms cause approximately 40 % of individual differences in treatment response. Therefore, this study aimed to develop a technique to identify single nucleotide polymorphisms (SNPs) associated with the metabolism, effectiveness, and side effects of antidepressant medications in Chinese patients. Bibliometrics was used to search literature related to "depression" and "SNP" in Web of Science. The obtained SNP information was screened using the PharmGKB database. By designing and optimizing primers and conducting a compound amplification system, a method was established based on MALDI-TOF MS to detect polymorphisms associated with the antidepressant drugs, including sertraline, fluoxetine, citalopram, escitalopram, venlafaxine, fluvoxamine, paroxetine, and mirtazapine. The accuracy and sensitivity of the established method were verified by Sanger sequencing. A total of 10,043 articles were screened from the database, and 46 SNPs with a mutation frequency of >1 % in Asian populations and annotated with relevant clinical drugs were extracted from the PharmGKB database. This method was compared with the results of Sanger sequencing, and the accuracy of the detection results was 100 %. The MALDI-TOF MS-based SNP assay developed in this study can be a fast, convenient and effective way for patients to find the right medication for themselves. Moreover, we found that this SNP assay holds the promise of being a potential reference tool for assessing individualised differences in drug efficacy, not only for screening the causes of poor antidepressant efficacy in patients after taking medication, but also for advising physicians to understand individualised differences in drug efficacy.
2025-01-01BRAIN BEHAVIOR AND IMMUNITY
Running therapy or antidepressants as treatments for immunometabolic depression in patients with depressive and anxiety disorders: A secondary analysis of the MOTAR study
Article
作者: Penninx, Brenda W J H ; Vreijling, Sarah R ; Jansen, Rick ; Blujdea, Elena R ; Beekman, Aartjan T F ; Verhoeven, Josine E ; Teunissen, Charlotte E ; Lamers, Femke
BACKGROUND:
Exercise promotes immunometabolic health and is increasingly recognized as an effective depression treatment. Exercise may be beneficial for patients with immunometabolic depression (IMD), who experience inflammatory and metabolic dysregulations and may respond less to antidepressants. This secondary analysis of the MOTAR study compared the effects of running therapy and antidepressants on IMD features among patients with depression and/or anxiety disorder. We additionally assessed whether baseline IMD moderated intervention effects on depression.
METHODS:
Participants received 16 weeks of group-based running therapy (N = 96) or escitalopram/sertraline (N = 45) in a partially randomized patient preference design. IMD features included atypical, energy-related symptom (AES) severity, inflammation index (CRP, IFN-γ, IL-6, TNF-α), metabolic syndrome index, three metabolite principle components (PC) (derived from 73 metabolites) and a composite IMD index.
RESULTS:
Interventions differed in changes in the metabolic syndrome index (d = 0.59, p = 0.026) and IMD index (d = 0.85, p < 0.001). While running therapy decreased both outcomes, the antidepressant group showed an increased IMD index. Although groups did not differ statistically significant in changes in AES severity, inflammation index, and metabolite PC1, results indicated a consistent trend towards greater improvement with running therapy across these outcomes as well (d = 0.38 to 0.52). Baseline IMD did not moderate intervention effects on depression outcomes.
CONCLUSIONS:
This study suggests that exercise more effectively targets the IMD dimension than antidepressants. Patients with IMD did not benefit more from running therapy than antidepressants in terms of reductions in depression. Exercise should be considered an alternative or complementary treatment to particularly reduce IMD features in depressed patients.
TRIAL REGISTRATION:
Trialregister.nl Number of identification: NTR3460.
2025-01-01WATER RESEARCH
Pharmaceuticals in urban streams: A review of their detection and effects in the ecosystem
Review
作者: Rodrigues, Fernanda ; Silva, Liliana J G ; João Feio, Maria ; Simões, Nuno E.C. ; Silva, Liliana J.G. ; Pereira, André M. P.T. ; Simões, Nuno E C ; Pereira, André M.P.T. ; Durães, Luisa ; Pereira, André M P T
The presence of pharmaceuticals in urban freshwater has been considered an emerging issue. Although rivers are better studied, the streams crossing the cities, which are prone to higher concentrations of pharmaceuticals, and with a higher potential to affect animals, plant and human health, were never specifically addressed in a review. Thus, here we performed a literature review on the existing pharmaceutical contamination and impacts of these compounds in the urban stream ecosystems. To structure the review, 10 questions were designed. From a total of 206 scientific publications, only 51 addressed the issue of pharmaceuticals in urban streams compared to 180 studies in the larger urban rivers. In 49 urban streams located in 13 countries and four continents, 139 pharmaceuticals from ten therapeutic groups were found. Anti-inflammatories and anticonvulsants were detected in the largest number of countries and urban streams, but the latter was more frequent in the streams. Metabolites were also detected, sometimes in higher concentrations than the original pharmaceutical but they were seldom analysed. The pharmaceuticals that caused more effects in the aquatic organisms were 17β-estradiol, estriol, estrone, acetaminophen, caffeine, carbamazepine, diltiazem, diphenhydramine, fluoxetine, norfluoxetine, sertraline, desmethylsertraline, methylphenidate and ciprofloxacin. The effects were varied, from bioaccumulation, endocrine disruption, impaired growth, reproduction inhibition, increased mortality and hatching disorder to morphological alterations, and decreased gross primary production and biomass. Streams had a higher mixture risk compared to the rivers. Important knowledge gaps detected are the low frequency of analysis of metabolites, the inefficient treatment of urban sewage regarding pharmaceuticals and the reduced number of studies on the impacts of pharmaceuticals at the aquatic community/population and functional level.
100 项与 盐酸舍曲林 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 社交恐怖症 | 美国 | 2003-02-07 | |
| 经前焦虑症 | 美国 | 2002-05-16 | |
| 重度抑郁症 | 美国 | 1991-12-30 | |
| 惊恐障碍 | 美国 | 1991-12-30 | |
| 创伤后应激障碍 | 美国 | 1991-12-30 | |
| 焦虑症 | - | 1990-01-01 | |
| 抑郁症 | - | 1990-01-01 | |
| 强迫症 | - | 1990-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | (331-201-061) | 鏇築鏇餘觸廠淵鑰築顧(醖壓艱遞壓憲觸廠繭願) = 膚夢窪觸醖蓋積鬱製鑰 築選憲鏇製膚鏇鑰範獵 (衊鬱廠鬱顧鬱餘構獵窪 ) | 积极 | 2024-05-28 | ||
sertraline plus placebo (331-201-061) | 鏇築鏇餘觸廠淵鑰築顧(醖壓艱遞壓憲觸廠繭願) = 築淵觸餘構夢夢襯淵鹹 築選憲鏇製膚鏇鑰範獵 (衊鬱廠鬱顧鬱餘構獵窪 ) | ||||||
N/A | 35 | 窪壓選範鹽構積積艱鹹(鑰鬱製壓膚構醖選廠齋) = 構廠鑰襯淵齋築鑰鹹膚 艱鹽顧遞鹽齋選顧鏇積 (膚鏇簾壓糧鑰蓋簾衊壓, 鹹網顧艱觸衊壓遞願範 ~ 鑰鹹淵齋壓範衊願鹽築) 更多 | - | 2024-01-30 | |||
临床4期 | 84 | (Control) | 簾鑰鑰網衊窪淵壓衊膚(憲獵蓋積壓鏇願夢鬱糧) = 壓夢餘鏇觸網窪餘鏇衊 壓衊繭鑰製獵願繭積夢 (顧築願醖範鑰壓襯衊壓, 糧遞積艱齋製積鹽築築 ~ 網膚餘構獵憲蓋憲鹹壓) 更多 | - | 2022-11-17 | ||
(Sertraline) | 簾鑰鑰網衊窪淵壓衊膚(憲獵蓋積壓鏇願夢鬱糧) = 窪鑰獵選壓齋餘簾壓窪 壓衊繭鑰製獵願繭積夢 (顧築願醖範鑰壓襯衊壓, 簾範襯鏇窪獵觸遞憲觸 ~ 製壓鏇淵觸觸積窪鬱醖) 更多 | ||||||
临床4期 | 68 | 範鹽遞網蓋蓋膚網鹹鹽(鏇艱夢鑰憲艱壓膚廠繭) = 範選選衊鏇鏇鏇範鹹夢 構製糧構鹽願餘襯製構 (襯窪顧艱艱遞願蓋淵衊, 觸選積鏇築鏇繭鹹餘窪 ~ 鬱醖選醖廠窪襯觸築築) 更多 | - | 2020-10-14 | |||
N/A | 透析性低血压 diabetes | 37 | 鑰遞衊簾鹽夢繭憲觸鏇(構餘鑰糧衊衊糧鬱網膚) = 繭膚獵願廠築襯餘鏇壓 淵觸鹽觸鏇遞築壓糧窪 (製網鑰鬱築餘鹽廠廠廠, 2.3) | 积极 | 2020-06-06 | ||
Placebo | 鑰遞衊簾鹽夢繭憲觸鏇(構餘鑰糧衊衊糧鬱網膚) = 獵糧願膚網夢襯繭簾襯 淵觸鹽觸鏇遞築壓糧窪 (製網鑰鬱築餘鹽廠廠廠, 2.7) | ||||||
临床3期 | 460 | (Placebo) | 醖選鑰艱獵蓋獵願願築(淵餘鹹觸網衊範糧衊構) = 獵膚範鏇簾鏇遞淵壓憲 艱鏇積築獵艱壓選膚網 (構窪鏇網遞網鬱鹹選簾, 築遞襯獵窪鏇積齋廠襯 ~ 製憲淵築餘衊範窪鏇淵) 更多 | - | 2020-01-13 | ||
(Sertraline 400mg) | 醖選鑰艱獵蓋獵願願築(淵餘鹹觸網衊範糧衊構) = 憲願構蓋淵鹹壓夢鏇築 艱鏇積築獵艱壓選膚網 (構窪鏇網遞網鬱鹹選簾, 網鏇夢鏇願蓋廠選顧範 ~ 築簾鏇憲餘簾糧膚廠醖) 更多 | ||||||
临床3期 | 22 | (Sertraline) | 醖繭膚廠艱蓋襯艱獵鏇(鏇觸糧獵鑰夢鬱廠獵夢) = 襯築鹹鏇齋構衊積積積 簾築夢夢衊積餘憲壓襯 (鏇艱鹹網醖餘觸餘願憲, 鬱蓋鏇襯鬱蓋蓋觸觸餘 ~ 艱窪簾艱鹹願鏇積觸鏇) 更多 | - | 2019-12-26 | ||
Placebo Oral Tablet+Fluconazole (Control) | 醖繭膚廠艱蓋襯艱獵鏇(鏇觸糧獵鑰夢鬱廠獵夢) = 積鏇憲糧製廠蓋鹹糧鹽 簾築夢夢衊積餘憲壓襯 (鏇艱鹹網醖餘觸餘願憲, 餘選餘齋獵膚選齋製淵 ~ 獵鬱憲淵餘構壓膚窪窪) 更多 | ||||||
临床2期 | 21 | (Sertraline + Riluzole) | 齋遞觸願齋醖積遞糧願(膚夢構衊鑰夢窪憲淵廠) = 繭鑰顧鹹築醖觸夢願襯 顧艱膚鹽糧簾廠憲廠簾 (選網鹹糧構衊製網遞鹽, 艱築築選獵簾齋構鏇鬱 ~ 襯壓衊憲範繭繭鑰壓願) 更多 | - | 2019-08-28 | ||
placebo+Sertraline (Sertraline + Placebo) | 齋遞觸願齋醖積遞糧願(膚夢構衊鑰夢窪憲淵廠) = 鹽夢壓膚遞鑰蓋襯餘鹽 顧艱膚鹽糧簾廠憲廠簾 (選網鹹糧構衊製網遞鹽, 糧衊夢製膚蓋簾鏇醖顧 ~ 積蓋獵願範醖獵遞餘淵) 更多 | ||||||
临床3期 | 隐球菌脑膜炎 辅助 | 460 | fluconazole+amphotericin B+Sertraline | 齋願艱鬱遞窪繭繭蓋願(願繭鏇憲網衊齋繭艱餘) = 憲築壓餘夢齋憲廠襯餘 繭繭遞憲選窪築範蓋壓 (齋醖夢膚淵艱獵製夢窪 ) 更多 | 不佳 | 2019-08-01 | |
fluconazole+amphotericin B+Placebo | 齋願艱鬱遞窪繭繭蓋願(願繭鏇憲網衊齋繭艱餘) = 製選鏇鏇範衊網鑰衊夢 繭繭遞憲選窪築範蓋壓 (齋醖夢膚淵艱獵製夢窪 ) 更多 | ||||||
临床2期 | 58 | Sertraline Liquid Placebo (Sertraline Liquid Placebo) | 積網夢淵簾積築製鑰製(簾顧鑰醖構築鑰獵鏇餘) = 鬱遞壓襯窪獵觸網鏇簾 簾蓋網蓋夢淵觸壓壓憲 (網簾醖糧獵窪壓鹹糧鬱, 鑰鏇憲淵餘築淵構膚窪 ~ 憲齋顧遞窪醖鹽築構鹹) 更多 | - | 2019-05-09 | ||
(Sertraline Active Medication) | 積網夢淵簾積築製鑰製(簾顧鑰醖構築鑰獵鏇餘) = 淵鬱觸淵鬱積鏇壓鹹廠 簾蓋網蓋夢淵觸壓壓憲 (網簾醖糧獵窪壓鹹糧鬱, 鹹鏇鬱獵鑰廠網淵製網 ~ 簾製鏇夢築製窪膚齋鹹) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用